<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782208</url>
  </required_header>
  <id_info>
    <org_study_id>GHD01</org_study_id>
    <nct_id>NCT02782208</nct_id>
  </id_info>
  <brief_title>Lipolytic Effects of GH in Hypopituitary Patients in Vivo</brief_title>
  <official_title>Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growth hormone (GH) is essential for longitudinal bone growth and somatic development. These
      protein anabolic effects require sufficient nutritional supply. During fasting and caloric
      restriction GH predominantly promotes fat metabolism.

      GH counteracts the effect of insulin in many tissues, of which insulin-stimulated glucose
      uptake in skeletal muscle has been most extensively studied. Substrate competition between
      elevated free fatty acids and glucose is suggested as a mechanism, and this hypothesis can be
      tested mechanistically by means of acipimox, which is a nicotinic acid that suppresses the
      fat metabolizing effects of GH.

      The hypothesis is, that the suppressive effect of GH on insulin-stimulated glucose uptake in
      skeletal muscle is obviated by acipimox-induced inhibition of fat metabolism.

      In order to investigate this, eight adult hypopituitary patients with documented
      GH-deficiency will be studied in the presence and absence of GH and acipimox, respectively,
      and biopsies from skeletal muscle and subcutaneous adipose tissue will be analyzed.

      Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in
      long-sight have great importance for the understanding of growth disorders from overweight
      and type 2 diabetes to malnutrition and eating disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipolytic activity measured as area under the curve (AUC) for FFA (free fatty acid) before and during clamp-conditions.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GH signaling proteins and gene targets in adipose and skeletal muscle tissues measured by western blotting and qPCR</measure>
    <time_frame>1,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity as measured by M value and GIR (glucose infusion rate)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substrate metabolism as measured by indirect calorimetry, tritiated glucose and circulating hormones and metabolites</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDH (pyruvate dehydrogenase) activity in skeletal muscle measured by an PDH activity assay</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Hypopituitarism</condition>
  <condition>Insulin Resistance</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Pituitary Diseases</condition>
  <condition>Brain Diseases</condition>
  <arm_group>
    <arm_group_label>Acipimox/GH substitution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acipimox/GH pause</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/GH substitution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo tablets Continue GH substitution as usually.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/GH pause</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo tablets Pause GH substitution to days prior to the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.</description>
    <arm_group_label>Acipimox/GH substitution</arm_group_label>
    <arm_group_label>Acipimox/GH pause</arm_group_label>
    <other_name>Olbetam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered 4 times previous to and during the investigation day.</description>
    <arm_group_label>Placebo/GH substitution</arm_group_label>
    <arm_group_label>Placebo/GH pause</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GH substitution</intervention_name>
    <description>GH substitution as usually</description>
    <arm_group_label>Acipimox/GH substitution</arm_group_label>
    <arm_group_label>Placebo/GH substitution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GH pause</intervention_name>
    <description>GH substitution pause two days prior to the experimental day</description>
    <arm_group_label>Acipimox/GH pause</arm_group_label>
    <arm_group_label>Placebo/GH pause</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypopituitary patients with documented GH-deficiency

        Exclusion Criteria:

          -  other significant disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Otto L Jørgensen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astrid J Hjelholt, MD</last_name>
    <phone>+4524800664</phone>
    <email>ajh@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Otto L Jørgensen, Professor</last_name>
    <phone>+4520727383</phone>
    <email>joj@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid J Hjelholt, MD</last_name>
      <phone>+4524800664</phone>
      <email>ajh@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3.</citation>
    <PMID>12563315</PMID>
  </reference>
  <reference>
    <citation>Nellemann B, Vendelbo MH, Nielsen TS, Bak AM, Høgild M, Pedersen SB, Biensø RS, Pilegaard H, Møller N, Jessen N, Jørgensen JO. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol (Oxf). 2014 Feb;210(2):392-402. doi: 10.1111/apha.12183. Epub 2013 Nov 22.</citation>
    <PMID>24148194</PMID>
  </reference>
  <reference>
    <citation>Clasen BF, Poulsen MM, Escande C, Pedersen SB, Møller N, Chini EN, Jessen N, Jørgensen JO. Growth hormone signaling in muscle and adipose tissue of obese human subjects: associations with measures of body composition and interaction with resveratrol treatment. J Clin Endocrinol Metab. 2014 Dec;99(12):E2565-73. doi: 10.1210/jc.2014-2215.</citation>
    <PMID>25050904</PMID>
  </reference>
  <reference>
    <citation>Krusenstjerna-Hafstrøm T, Clasen BF, Møller N, Jessen N, Pedersen SB, Christiansen JS, Jørgensen JO. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab. 2011 Aug;96(8):2548-57. doi: 10.1210/jc.2011-0273. Epub 2011 May 25.</citation>
    <PMID>21613350</PMID>
  </reference>
  <reference>
    <citation>Nielsen TS, Jessen N, Jørgensen JO, Møller N, Lund S. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol. 2014 Jun;52(3):R199-222. doi: 10.1530/JME-13-0277. Epub 2014 Feb 27. Review.</citation>
    <PMID>24577718</PMID>
  </reference>
  <reference>
    <citation>Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152-77. doi: 10.1210/er.2008-0027. Epub 2009 Feb 24. Review.</citation>
    <PMID>19240267</PMID>
  </reference>
  <reference>
    <citation>Nielsen S, Møller N, Christiansen JS, Jørgensen JO. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes. 2001 Oct;50(10):2301-8.</citation>
    <PMID>11574412</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Hypopituitarism</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

